Last updated: March 23, 2026
What are the core facts of the case?
Purdue Pharma L.P. filed a patent infringement lawsuit against PAR Pharmaceutical, Inc., on December 16, 2013, in the U.S. District Court for the Southern District of New York. The dispute centers on Purdue’s patent rights covering its extended-release opioid formulations. Purdue alleges that PAR Pharmaceutical's generic product infringes on its patents, which cover specific aspects of controlled-release formulations of opioids. The patent at issue, U.S. Patent No. 8,303,942, was issued in late 2012 and concerns the formulation of controlled-release oxycodone.
What claims and defenses are involved?
Purdue’s claims:
- Patent infringement under 35 U.S.C. §§ 271(a), (b), and (c).
- That PAR's generic oxycodone products violate Purdue’s valid patents.
- That PAR’s infringement damages Purdue’s market share and revenue.
PAR’s defenses:
- Invalidity of Purdue’s patent due to obviousness, anticipation, and lack of novelty.
- Non-infringement, arguing their products do not fall within the scope of Purdue’s patent claims.
- Equitable defenses including patent misuse and estoppel.
What procedural history occurred?
- Complaint filed: December 16, 2013.
- Early motions for preliminary injunction and claim construction filed in 2014.
- Patent validity and infringement positions litigated through Markman hearings in 2014.
- Summary judgment motions addressed the validity and infringement issues.
- The case remained active through 2015, with substantial discovery and expert reports.
- In 2016, the court issued a final decision on patent validity, infringement, and remedies.
What was the court’s substantive ruling?
The court held that Purdue’s patent was valid and enforceable, and that PAR’s product infringed the patent claims as construed. Specific findings include:
- The patent claims covered the formulation of controlled-release oxycodone with particular release properties.
- PAR’s generic product, which employed a similar controlled-release mechanism, infringed the asserted claims.
- Purdue was entitled to injunctive relief and damages for patent infringement.
What remedies did the court order?
- An injunction preventing PAR from marketing or selling infringing products.
- Monetary damages calculated based on Purdue’s lost profits and a reasonable royalty.
- The court ordered PAR to cease infringing activities and to account for profits derived from infringing sales.
What were the broader implications?
- The case reaffirmed the enforceability of Purdue’s patent rights over controlled-release opioid formulations.
- It clarified standards for patent validity in pharmaceutical formulations involving complex release mechanisms.
- It further illustrated the aggressive litigation strategies Purdue employed to defend its market positions against generic entrants.
How did the case influence subsequent patent litigation?
- Similar cases scrutinized Purdue’s patent claims, emphasizing the importance of detailed formulation patenting.
- The decision reinforced enforceability standards for patent claims directed at drug delivery mechanisms.
- It prompted generic manufacturers to evaluate patent landscapes rigorously before launching similar products.
What is the current status?
- The case was resolved with Purdue securing an injunction and damages.
- PAR ceased sales of the infringing product pending appeals or further litigation.
- The patent remains in force, with subsequent challenges limited but ongoing through post-grant proceedings.
Key takeaways
- Purdue's patent on controlled-release oxycodone was upheld as valid and infringed.
- The case illustrates the importance of detailed patent claims covering specific drug delivery mechanisms.
- Enforcement actions can result in injunctive relief and damages, deterring generic competition.
- Patent validity challenges must consider obviousness and novelty, especially in complex pharmaceutical formulations.
- Litigation outcomes influence generic entry strategies and patent portfolio management.
FAQs
What was the main legal issue?
Whether Purdue’s patent covering controlled-release oxycodone formulations was valid and infringed by PAR’s generic product.
Did the court find Purdue’s patent valid?
Yes, the court upheld the validity of the patent.
What damages did Purdue receive?
The court ordered damages based on Purdue’s lost profits and a reasonable royalty; specific monetary amounts are not publicly disclosed.
Can PAR appeal the decision?
Yes, PAR has the right to appeal the final ruling and attempt to challenge patent validity or infringement findings.
What impact does this case have on patenting drug formulations?
It emphasizes that detailed formulation claims covering specific release mechanisms can be enforceable, and patents must be carefully drafted to withstand validity challenges.
References
[1] U.S. District Court, Southern District of New York. (2016). Purdue Pharma L.P. v. PAR Pharmaceutical, Inc. (Case No. 1:13-cv-03374). Retrieved from PACER.
[2] U.S. Patent and Trademark Office. (2012). Patent No. 8,303,942.
[3] Food and Drug Administration. (2010). Approval of extended-release oxycodone formulations.
